Lab / RNA-based multi-cancer early detection diagnostics; Southeast Asia's first biotech unicorn (HKEX IPO May 2025)
Mirxes
Mirxes is a Singapore-founded biotech diagnostics company specializing in miRNA-based liquid biopsy and early cancer detection, achieving Southeast Asia's first biotech unicorn status upon its HKEX IPO in May 2025. Its flagship products include GASTROClear (the world's first blood test for gastric cancer early detection, FDA Breakthrough Device designated) and LUNGClear for lung cancer. The company operates clinical sequencing, precision multiomics, and biobanking services through a public-private partnership center for specialty molecular testing in Singapore.
Relationships
EDBI, Mitsui, Venturecraft, CBC Group R-Bridge
Key people
- Zhou Lihan (Co-Founder and CEO, PhD Biochemistry NUS); Zou Ruiyang (Co-Founder and CTO, PhD NUS-MIT Alliance); Prof. Too Heng Phon (Co-Founder and Chief Scientific Advisor, NUS)